Skip to main content

Advertisement

ADVERTISEMENT

CIO Abstracts

Purpose: To report outcomes of an institutional downstaging protocol for intrahepatic cholangiocarcinoma (iCCA) using radioembolization (TARE), gemcitabine, cisplatin, and capecitabine co...
11/02/2023
Purpose: To identify factors of incomplete treatment after segmental transarterial radioembolization (TARE) for treatment-naïve and solitary hepatocellular carcinoma (HCC)
11/02/2023
Purpose: The procedural and clinical outcomes of a transradial approach (TRA) versus a transfemoral approach (TFA) for interventional oncology (IO) procedures remain unclear.
11/02/2023
Purpose: Long term care of patient's with complicated disease processes often incurs significant financial burden. This burden if often complicated with misuse or failure of medical devic...
11/02/2023
Purpose: The purpose of this case study is to investigate the interesting complications that may arise from uterine Leiomyomas. Uterine Leiomyomas are extremely common in the female popul...
11/01/2023
Purpose: The purpose of this case study is to exhibit the successful treatment of metastatic liposarcoma in an elderly male patient via Pulsed Electric Fields (PEF) monotherapy.
11/01/2023
Purpose: Colorectal malignancy ranks as the third most prevalent global cancer, with liver metastases being the most common spread site. Surgery is considered the gold standard treatment ...
11/01/2023
Purpose: Histotripsy, an emerging advanced technology, offers a non-invasive approach to tumor removal without heat or ionizing radiation. By utilizing ultrasound, it creates small bubble...
11/01/2023
Purpose: Intrahepatic cholangiocarcinoma (ICC) is a progressive disease with a poor prognosis. Surgical resection is curative, but most patients with ICC are ineligible. While systemic th...
11/01/2023
IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab vs surveillance in hepatocellular carcinoma patients
Purpose: The risk of HCC recurrence after liver resection or ablation with curative intent is 70-80% within 5 years, indicating an unmet need for effective adjuvant therapies. Atezolizuma...
11/01/2023

Advertisement

Advertisement

Advertisement